@misc{misc, title  = {{345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis}},

 url = {{}},

 year = {{2023}},

 month = {{1}},

 author = {{Weidinger S and Cork M and Reich A and Bieber T and Gilbert S and Brennan N and Wilson R and Lucchesi D and Rynkiewicz N and Stebegg M and Porter-Brown B}},

 note = {{Accessed on 2024/12/22}}}